34. Automation and Regenerative Manufacturing, Alexander Titus, Chief Strategy Officer, ARMI

34. Automation and Regenerative Manufacturing, Alexander Titus, Chief Strategy Officer, ARMI

Alexander Titus is the Founder of Bioeconomy.XYZ and the Chief Strategy Officer (CSO) at the Advanced Regenerative Manufacturing Institute (ARMI), where his career focuses on the intersection of technology and public benefit, with experience spanning the private and public sectors, as well as non-profits and academia. In previous roles, Alexander was the inaugural Assistant Director (AD) for Biotechnology within the Office of the CTO at the Department of Defense (DoD). As the AD for Biotechnology, Alexander was the DASD-level senior executive in charge of the DoD’s enterprise strategy for biotechnology, where he led the team developing the biotechnology modernization roadmap for the DoD. Alexander joined the DoD from McKinsey & Company, where he was a management consultant and a member of the inaugural cohort of Defense & Security Specialists working with the national security community on high-priority issues related to organization effectiveness, leadership, and analytics. On the technical side, Alexander is a trained data scientist with an expertise at the intersection of AI and biology. Prior to consulting, Alexander was a data scientist at the venture capital firm In-Q-Tel, as a member of their B. Next group, as well as a data scientist at Amazon on the Alexa AI team and at Dartmouth in the Geisel School of Medicine. Alexander holds a PhD in Quantitative Biomedical Sciences from the Guarini School of Graduate and Advanced Studies at Dartmouth, as well as a BS and BA in biochemistry and biology (respectively) from the University of Puget Sound.

Det här avsnittet är hämtat från ett öppet RSS-flöde och publiceras inte av Podme. Det kan innehålla reklam.

Avsnitt(261)

Ardelyx Leaders Mike Raab & Laura Williams on Building Biotech Around Patients

Ardelyx Leaders Mike Raab & Laura Williams on Building Biotech Around Patients

Synopsis: While biotech is increasingly measured by clinical milestones and financial outcomes, Rahul Chaturvedi welcomes two leaders who argue that true success begins and ends with patients. In th...

10 Juni 41min

Acadia CEO Catherine Owen Adams on Neurodegeneration, AI & Building Biotech Vision

Acadia CEO Catherine Owen Adams on Neurodegeneration, AI & Building Biotech Vision

Synopsis: At the intersection of personal mission and biotech leadership, Rahul Chaturvedi sits down with Catherine Owen Adams, CEO of Acadia Pharmaceuticals, for a deeply personal and strategically...

13 Maj 33min

Barry Quart, CEO of Connect Biopharma, on Asthma Innovation & Biotech Leadership

Barry Quart, CEO of Connect Biopharma, on Asthma Innovation & Biotech Leadership

Synopsis: This episode is proudly sponsored by Quartzy. At a time when biotech innovation is being reshaped by science, capital, and global dynamics, Alok Tayi sits down with Barry Quart, CEO of Co...

16 Apr 23min

Adial CEO Cary Claiborne on Treating Alcohol Addiction with Genetics

Adial CEO Cary Claiborne on Treating Alcohol Addiction with Genetics

Synopsis: Addiction is often misunderstood as a failure of willpower—but emerging science increasingly shows it may be deeply rooted in biology. In this episode of Biotech 2050, recorded during JPM...

6 Mars 14min

Sheila Gujrathi, MD on Leadership, Biotech Innovation & The Mirror Effect for Women Leaders

Sheila Gujrathi, MD on Leadership, Biotech Innovation & The Mirror Effect for Women Leaders

Synopsis: This episode is proudly sponsored by Quartzy. Physician-scientist, biotech founder, and leadership advocate Sheila Gujrathi, MD joins Rahul Chaturvedi on the Biotech 2050 Podcast for a po...

5 Mars 39min

Fred Aslan, Artiva CEO, on Cell Therapy’s Next Wave, RA Trials & Scalable NK Platforms

Fred Aslan, Artiva CEO, on Cell Therapy’s Next Wave, RA Trials & Scalable NK Platforms

Synopsis: At the heart of JPM 2026’s biotech buzz, Alok Tayi sits down with Fred Aslan, CEO of Artiva, to explore how bold platform bets, scalable cell therapies, and autoimmune breakthroughs could ...

11 Feb 25min

Michelle Werner, CEO of Alltrna, on tRNA Platforms, Rare Disease & Drug Innovation

Michelle Werner, CEO of Alltrna, on tRNA Platforms, Rare Disease & Drug Innovation

Synopsis: At JPM 2026 in San Francisco, Alok Tayi welcomes Michelle Werner, CEO of Alltrna, to Biotech 2050 for a powerful conversation at the intersection of personal mission, platform biology, and...

10 Feb 26min

Brian Hilberdink on Boehringer’s U.S. Growth, AI & Pharma’s Next Frontier

Brian Hilberdink on Boehringer’s U.S. Growth, AI & Pharma’s Next Frontier

Synopsis: From managing a theme park in Canada to leading the U.S. business of one of the world’s largest privately held pharma companies, Brian Hilberdink’s journey is anything but conventional. Li...

28 Jan 21min

Populärt inom Vetenskap

p3-dystopia
dumma-manniskor
allt-du-velat-veta
kapitalet-en-podd-om-ekonomi
rss-ufobortom-rimligt-tvivel
medicinvetarna
rss-vetenskapsradion
svd-nyhetsartiklar
bildningspodden
rss-vetenskapsradion-2
vetenskapsradion
paranormalt-med-caroline-giertz
halsorevolutionen
det-morka-psyket
dumforklarat
rss-spraket
sexet
rss-ronden
rss-geopodden-2
rss-broccolipodden-en-podcast-som-inte-handlar-om-broccoli